- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 10th, 2005
Jack Uldrich: Shares of Elan (NYSE: ELN) and Motley Fool Stock Advisor recommendation Biogen Idec (Nasdaq: BIIB) jumped 14% and 7%, respectively, on yesterday's news that a recent Elan study found no new confirmed cases of the brain disease, PML, in patients who had taken Tysabri -- a promising multiple sclerosis-fighting drug that was pulled this spring after the deaths of three patients were linked to it.
Tuesday's news obviously bolstered investor confidence that Tysabri will make its way back onto the market, but does that make Elan a good investment opportunity? The answer is "no" in the short term and "yes" in the long term.
|Related News Press|
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015